508. Bone Marrow Failure: Acquired: Poster III

Study design of A phase 3 open label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis

Real world data on breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with proximal and terminal complement inhibitors

Invariant patterns of global mutational signatures allow new fundamental insights in etiopathogenesis of bone marrow failure including aplastic anemia and myelodysplasia

Real world data on cardiovascular disease incidence in adults with acquired immune aplastic anemia

The CSMD1 gene is involved in hematopoietic stem cell HSC pruning in patients with acquired immune mediated aplastic anemia

Apply PNH Analysis of complement pathway biomarkers provides evidence for pharmacodynamic response in PNH patients who receive oral iptacopan monotherapy versus continuing anti C5 therapy

The 2 year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll over extension program

Autoimmunity against POLR3A and cytopenias in aplastic anemia and other bone marrow failure syndromes

Luspatercept combined with immunosuppressive therapy reduces inflammation in aplastic anemia by inhibiting monocyte pyroptosis

Serum ferritin changes in iptacopan treated patients with paroxysmal nocturnal hemoglobinuria

Factor bb as a biomarker during breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria

Immune subset clonality profiling in aplastic anemia A highly sensitive flow cytometry approach to differentiate acquired and inherited syndromes

The role of red blood cell lifespan in evaluating the condition of patients with paroxysmal nocturnal hemoglobinuria treated with complement inhibitors

Real world clinical characteristics and treatment outcomes in PNH patients prescribed pegcetacoplan across europe the United States and Canada

Efficacy and safety of HSK39297 monotherapy in patients with paroxysmal nocturnal hemoglobinuria PNH